The results of the COMPASSION-15 study were previously orally presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting. This recognition represents an additional validation ...

In September 2024, the cadonilimab regimen for the first-line treatment of advanced gastric cancer was approved and is now widely used in clinical practice, offering a comprehensive and ...

Morningstar brands and products Company Portfolio ...

In September 2024, the cadonilimab regimen for the first-line treatment of advanced gastric cancer was approved and is now widely used in clinical practice, offering a comprehensive and ...